open access

Vol 61, No 6 (2010)
Original papers
Published online: 2010-11-15
Submitted: 2013-02-15
Get Citation

The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease

Robert Krysiak, Marian Sierant, Bogdan Marek, Bogusław Okopień
Endokrynologia Polska 2010;61(6):683-690.

open access

Vol 61, No 6 (2010)
Original papers
Published online: 2010-11-15
Submitted: 2013-02-15

Abstract


Introduction: It has been suggested that adipose tissue hormones are involved in the mechanism of action of angiotensin-converting enzyme (ACE) inhibitors. Very little is known as to whether the action on resistin contributes to the clinical effectiveness associated with the use of these agents.
Material and methods: The aim of this study was to compare the effects of plasma- and tissue-type ACE inhibitors (enalapril and perindopril) on plasma resistin content in coronary artery disease (CAD) individuals without arterial hypertension. The samples used in our analysis were obtained at baseline, and again after 30 and 90 days of treatment, from 22 patients receiving enalapril (20 mg/d), 24 receiving perindopril (4 mg/d), 20 receiving no angiotensin-converting enzyme inhibitors, and 20 healthy subjects. Each group consisted of patients sensitive and resistant to insulin.
Results: Plasma resistin content was higher in normotensive CAD patients, particularly in the subgroup with reduced insulin sensitivity, than in the control group. Both ACE inhibitors produced a weak effect on blood pressure. Perindopril treatment reduced resistin levels, while enalapril only tended to decrease its content. The effect of perindopril was stronger in insulin-resistant than in insulin-sensitive subjects.
Conclusions: Our results demonstrate the superiority of perindopril over enalapril in reducing plasma resistin levels, particularly in insulin-resistant subjects. They justify the choice of a tissue-type ACE inhibitor in normotensive CAD individuals, requiring administration of this group of agents.
(Pol J Endocrinol 2010; 61 (6): 683-690)

Abstract


Introduction: It has been suggested that adipose tissue hormones are involved in the mechanism of action of angiotensin-converting enzyme (ACE) inhibitors. Very little is known as to whether the action on resistin contributes to the clinical effectiveness associated with the use of these agents.
Material and methods: The aim of this study was to compare the effects of plasma- and tissue-type ACE inhibitors (enalapril and perindopril) on plasma resistin content in coronary artery disease (CAD) individuals without arterial hypertension. The samples used in our analysis were obtained at baseline, and again after 30 and 90 days of treatment, from 22 patients receiving enalapril (20 mg/d), 24 receiving perindopril (4 mg/d), 20 receiving no angiotensin-converting enzyme inhibitors, and 20 healthy subjects. Each group consisted of patients sensitive and resistant to insulin.
Results: Plasma resistin content was higher in normotensive CAD patients, particularly in the subgroup with reduced insulin sensitivity, than in the control group. Both ACE inhibitors produced a weak effect on blood pressure. Perindopril treatment reduced resistin levels, while enalapril only tended to decrease its content. The effect of perindopril was stronger in insulin-resistant than in insulin-sensitive subjects.
Conclusions: Our results demonstrate the superiority of perindopril over enalapril in reducing plasma resistin levels, particularly in insulin-resistant subjects. They justify the choice of a tissue-type ACE inhibitor in normotensive CAD individuals, requiring administration of this group of agents.
(Pol J Endocrinol 2010; 61 (6): 683-690)
Get Citation

Keywords

perindopril; enalapril; coronary artery disease; insulin resistance; resistin

About this article
Title

The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease

Journal

Endokrynologia Polska

Issue

Vol 61, No 6 (2010)

Pages

683-690

Published online

2010-11-15

Bibliographic record

Endokrynologia Polska 2010;61(6):683-690.

Keywords

perindopril
enalapril
coronary artery disease
insulin resistance
resistin

Authors

Robert Krysiak
Marian Sierant
Bogdan Marek
Bogusław Okopień

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl